Analyses including the patients recruited through Manchester centres have identified that fewer than 20% of women with unselected BC included in this study would be eligible for BRCA-testing under current NHS National Test Directory criteria, with approximately half of the total BRCA1/BRCA2/PALB2 pathogenic variants occurring in this ineligible group [24]. This evidence concerns the gene PALB2 and breast cancer.